Department of Trauma, Hand and Reconstructive Surgery, Hospital of the Johann Wolfgang Goethe - University Frankfurt Am Main, Theodor-Stern-Kai 7, 60590, Frankfurt, Germany.
Department of Neurosurgery, Hospital of the Johann Wolfgang Goethe - University Frankfurt Am Main, Schleusenweg 2, 60528, Frankfurt, Germany.
World J Surg. 2019 Nov;43(11):2804-2811. doi: 10.1007/s00268-019-05072-1.
Venous thromboembolism (VTE) is recognized as a factor of morbidity and mortality in trauma patients suffering from severe blunt traumatic brain injury (TBI). The administration of pharmacological prophylaxis is broadly accepted as an effective therapy to prevent VTE events in trauma patients. Regardless of its ascertained efficacy, the risk of hematoma progression complicates the therapy in patients suffering from TBI: therefore, the optimal time to start prophylactic anticoagulation in these patients remains controversial.
All primary admissions to our level-1-trauma center between January 2012 and December 2016 were screened for severe blunt TBI with a head Abbreviated Injury Scale (AIS) ≥ 3. Patients who died within the first 24 h were excluded. Basic demographic results, thromboembolic events and progression of the intracranial hematoma were extracted from the patient's records. The patients were categorized into 4 groups according to start of VTE chemoprophylaxis: early ( < 24 h after hospitalization), intermediate (24-48 h), late ( > 48 h) and no therapy (no prophylactic anticoagulation within the first five days of hospitalization). A total of 292 patients with severe TBI were analyzed (early: n = 93, intermediate: n = 90, late: n = 74, no therapy: n = 35). The overall rate of intracranial bleeding progression was 13.6% after prophylactic anticoagulation was started.
No statistically significant differences were found in the frequency of intracranial bleeding progression comparing the different time groups (early 12.9% vs. intermediate 11.1% vs. late 17.6%; adj. p = 0.13). In patients with VTE chemoprophylaxis, no thromboembolic events were recorded. Male gender, age, head AIS and subarachnoidal hemorrhage were identified as independent risk factors associated with intracranial hematoma progression.
The early administration of VTE chemoprophylaxis within 24 h after admission in patients with severe TBI did not increase the risk of intracranial bleeding progression.
静脉血栓栓塞症(VTE)被认为是创伤患者严重钝性颅脑损伤(TBI)的发病率和死亡率的一个因素。药物预防被广泛认为是预防创伤患者 VTE 事件的有效治疗方法。尽管其疗效已确定,但在患有 TBI 的患者中,血肿进展的风险使治疗复杂化:因此,在这些患者中开始预防性抗凝治疗的最佳时间仍存在争议。
筛选 2012 年 1 月至 2016 年 12 月期间我们的 1 级创伤中心所有初次入院的患者,以确定是否存在头部损伤严重程度评分(AIS)≥3 的严重钝性 TBI。排除入院 24 小时内死亡的患者。从患者病历中提取血栓栓塞事件和颅内血肿进展的基本人口统计学结果。根据 VTE 化学预防开始时间,将患者分为 4 组:早期(住院后<24 小时)、中期(24-48 小时)、晚期(>48 小时)和无治疗(住院前 5 天内无预防性抗凝治疗)。共分析了 292 例严重 TBI 患者(早期:n=93,中期:n=90,晚期:n=74,无治疗:n=35)。开始预防性抗凝后,颅内出血进展的总发生率为 13.6%。
不同时间组之间颅内出血进展的频率无统计学差异(早期 12.9%vs. 中期 11.1%vs. 晚期 17.6%;调整后 p=0.13)。在接受 VTE 化学预防的患者中,未记录到血栓栓塞事件。男性、年龄、头部 AIS 和蛛网膜下腔出血被确定为与颅内血肿进展相关的独立危险因素。
在严重 TBI 患者入院后 24 小时内早期给予 VTE 化学预防不会增加颅内出血进展的风险。